Over the past few years, lung cancer no longer remains among men only but is also on the rise among women. This is primarily due to shifts in smoking habits and environmental…
High-Dose Aumoltertinib for Untreated EGFR- Variant NSCLC
Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…
Taletrectinib Received FDA Approval for ROS1-Positive NSCLC
Recently, FDA has granted approval to Taletrectinib for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer in adults. Taletrectinib has demonstrated high response rates and was well tolerated among…
Study: New Nanoparticles Therapy for Lung Cancer Patients
A new research led by Gaurav Sahay of Oregon State University’s College ir Pharmacy was conducted in collaboration with Oregon Health & Science University and the University of Helsinki. In this study,…
Tarlatamab Shows Improved Overall Survival Over Chemotherapy in SCLC
Tarlatamab received accelerated approval for treatment of patients with previously treated small-cell lung cancer. It meaningfully improved overall survival compared with Chemotherapy in SCLC patients that progressed on or after initial platinum-based…
Study: Wildfire Smoke Exposure Affects Lung Cancer Survival
Wildfire Smoke is more toxic in comparison with normal air pollution. It contains traces of chemicals, metals and other synthetic materials in addition to soil and biological materials. A California study has…
Predicting Lung Cancer Risk with AI based Deep Learning Model
New research has been presented during the American Thoracic Society 2025 International Conference. This new deep learning model was able to predict lung cancer risk by using low-dose CT screening exam. The…
FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC
The FDA has granted accelerated approval to Telisotuzumab vedotin for the treatment of patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-MET protein overexpression. This approval is…